ExodusPoint Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

ExodusPoint Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-313,004	Closed	-$673K	–	2175
2024 Q3	$673K	Buy	313,004 +49,313	+19%	+$177K	﹤0.01%	1096
2024 Q2	$1.36M	Buy	263,691 +108,702	+70%	+$571K	0.01%	915
2024 Q1	$829K	Buy	154,989 +51,467	+50%	+$356K	0.01%	1002
2023 Q4	$806K	Sell	103,522 -4,615	-4%	-$15.8K	0.01%	892
2023 Q3	$427K	Sell	108,137 -10,261	-9%	-$38.4K	﹤0.01%	1294
2023 Q2	$373K	Sell	118,398 -3,157	-3%	-$10.1K	﹤0.01%	1456
2023 Q1	$325K	Buy	121,555 +87,390	+256%	+$339K	﹤0.01%	1454
2022 Q4	$123K	Buy	+34,165	New	+$148K	﹤0.01%	1507
2021 Q4	–	Sell	-3,068	Closed	-$137K	–	2693
2021 Q3	$137K	Buy	+3,068	New	+$150K	﹤0.01%	1857
2021 Q2	–	Sell	-1,078	Closed	-$81K	–	2906
2021 Q1	$81K	Sell	1,078 -911	-46%	-$94.6K	﹤0.01%	2002
2020 Q4	$216K	Buy	+1,989	New	+$181K	﹤0.01%	1695
2020 Q1	–	Sell	-3,678	Closed	-$254K	–	1739
2019 Q4	$254K	Buy	+3,678	New	+$223K	﹤0.01%	1233

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

ExodusPoint Capital Management's SYRS Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 313,004 shares — an estimated $673K sold.

ExodusPoint Capital Management first reported a position in SYRS in Q4 2019 and held it in 12 quarters. The position peaked at $1.36M in Q2 2024. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

ExodusPoint Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 313,004 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $673K.
ExodusPoint Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
ExodusPoint Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.36M in Q2 2024.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.